Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice

Aim. To assess efficiency and safety of therapy at the onset and after intensification of the treatment with biphasic insulin aspart 30/70 (NovoMix 30)in patients with type 2 diabetes who failed to reach the desired level of glycemic control by using other forms of insulin. Materials and methods....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina Vladimirovna Shestakova, Akil Ballan
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	type 2 diabetes mellitus insulin therapy aspart 30 (novomix 30) Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/8646b5500862485d859147d6c9193c45
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8646b5500862485d859147d6c9193c45
record_format	dspace
spelling	oai:doaj.org-article:8646b5500862485d859147d6c9193c452021-11-14T09:00:14ZTherapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice2072-03512072-037810.14341/2072-0351-6023https://doaj.org/article/8646b5500862485d859147d6c9193c452010-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6023https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To assess efficiency and safety of therapy at the onset and after intensification of the treatment with biphasic insulin aspart 30/70 (NovoMix 30)in patients with type 2 diabetes who failed to reach the desired level of glycemic control by using other forms of insulin. Materials and methods. The study included the Russian cohort of patients participating in the global IMPROVE program - a multi-center and multinationalopen observational non-randomized study for the evaluation of safety and efficiency of biphasic insulin aspart 30. Patients with type 2 diabetesmellitus were treated during 26 weeks under conditions of routine clinical practice. A total of 4869 patients enrolled in the program receivedantidiabetic treatment in the period preceding the study. 2430 of them were given oral hypoglycemic (OHG) agents alone and 2343 insulin +/- GHG.95 patients were preciously untreated. The dosage regime was prescribed by the attending physician on an individual basis. Most patients were poorlycompensated prior to the onset of the study. Their mean HbA1c level of 9.2% amounted to 9.9% in the untreated patients. Results of the treatment were analysed by the standard statistical methods for the entire cohort and for separate groups formed depending on previous therapeutic modality. Results. Six months after beginning of treatment with NovoMix 30, the HbA1c level significantly decreased by 2.34% in the entire cohort, 2.50% inthe previously untreated patients, and 2.13% in the two treated groups (pMarina Vladimirovna ShestakovaAkil BallanEndocrinology Research Centrearticletype 2 diabetes mellitusinsulin therapyaspart 30 (novomix 30)Nutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 1, Pp 92-100 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus insulin therapy aspart 30 (novomix 30) Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus insulin therapy aspart 30 (novomix 30) Nutritional diseases. Deficiency diseases RC620-627 Marina Vladimirovna Shestakova Akil Ballan Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
description	Aim. To assess efficiency and safety of therapy at the onset and after intensification of the treatment with biphasic insulin aspart 30/70 (NovoMix 30)in patients with type 2 diabetes who failed to reach the desired level of glycemic control by using other forms of insulin. Materials and methods. The study included the Russian cohort of patients participating in the global IMPROVE program - a multi-center and multinationalopen observational non-randomized study for the evaluation of safety and efficiency of biphasic insulin aspart 30. Patients with type 2 diabetesmellitus were treated during 26 weeks under conditions of routine clinical practice. A total of 4869 patients enrolled in the program receivedantidiabetic treatment in the period preceding the study. 2430 of them were given oral hypoglycemic (OHG) agents alone and 2343 insulin +/- GHG.95 patients were preciously untreated. The dosage regime was prescribed by the attending physician on an individual basis. Most patients were poorlycompensated prior to the onset of the study. Their mean HbA1c level of 9.2% amounted to 9.9% in the untreated patients. Results of the treatment were analysed by the standard statistical methods for the entire cohort and for separate groups formed depending on previous therapeutic modality. Results. Six months after beginning of treatment with NovoMix 30, the HbA1c level significantly decreased by 2.34% in the entire cohort, 2.50% inthe previously untreated patients, and 2.13% in the two treated groups (p
format	article
author	Marina Vladimirovna Shestakova Akil Ballan
author_facet	Marina Vladimirovna Shestakova Akil Ballan
author_sort	Marina Vladimirovna Shestakova
title	Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
title_short	Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
title_full	Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
title_fullStr	Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
title_full_unstemmed	Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
title_sort	therapy with biphasic insulin aspart 30/70 (novomix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a russian cohort of improve observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/8646b5500862485d859147d6c9193c45
work_keys_str_mv	AT marinavladimirovnashestakova therapywithbiphasicinsulinaspart3070novomix30improvesglycemiccontrolinpatientswithtype2diabetesmellitusresultsfromarussiancohortofimproveobservationalprogramdesignedtostudysafetyandefficiencyofbiphasicinsulinaspart30inroutineclinicalpractice AT akilballan therapywithbiphasicinsulinaspart3070novomix30improvesglycemiccontrolinpatientswithtype2diabetesmellitusresultsfromarussiancohortofimproveobservationalprogramdesignedtostudysafetyandefficiencyofbiphasicinsulinaspart30inroutineclinicalpractice
_version_	1718429666245607424

Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice

Ejemplares similares